Methotrexate - Therakind

Drug Profile

Methotrexate - Therakind

Alternative Names: Jylamvo; Methotrexate oral solution - Therakind

Latest Information Update: 21 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Therakind
  • Class Abortifacients; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Glutamates; Pterins; Small molecules
  • Mechanism of Action Immunosuppressants; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Juvenile rheumatoid arthritis; Precursor cell lymphoblastic leukaemia-lymphoma; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 21 Feb 2017 Chemical structure information added
  • 01 Feb 2017 Preregistration for Psoriasis (Treatment-resistant) in European Union (PO)
  • 26 Jan 2017 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of methotrexate oral solution for Rheumatoid arthritis, Psoriatic arthritis, Psoriasis (Treatment-resistant), Juvenile rheumatoid arthritis (In children, In adolescents) and Acute lymphoblastic leukaemia (In children, In adolescents, In adults, as a maintenance therapy) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top